192,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 192,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,852,000. Celldex Therapeutics accounts for approximately 1.2% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 14th biggest position. TFG Asset Management GP Ltd owned 0.29% of Celldex Therapeutics as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics during the fourth quarter worth $81,000. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the period. AlphaQuest LLC lifted its holdings in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics during the fourth quarter worth $121,000.

Analysts Set New Price Targets

Several brokerages recently weighed in on CLDX. The Goldman Sachs Group decreased their price target on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Friday, May 9th. Morgan Stanley cut their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. UBS Group cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research report on Monday, April 28th. They issued a “buy” rating and a $64.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $53.90.

Celldex Therapeutics Stock Up 1.7%

Shares of CLDX stock opened at $20.45 on Friday. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock has a market cap of $1.36 billion, a P/E ratio of -7.96 and a beta of 1.39. The business has a fifty day simple moving average of $18.91 and a 200-day simple moving average of $22.58.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.08 million. On average, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.